knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 22:04:13 - browse：9694

Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations, leaving her feeling helpless and bereft.

The first was her Polish-born maternal grandmother, who began showing symptoms when Schaeffer started college in 1981 and died seven years later. Then came her mother, a onetime Fulbright Scholar and high school language teacher who had been fluent in five languages but lost the ability to speak. She died in 2019. Last year, the disease killed Schaeffer’s mother’s sister, a former lab technician for Johnson & Johnson.

Schaeffer, a 59-year-old costume historian in North Berwick, Maine, has no symptoms of Alzheimer’s. But in 2021 her family history led her to apply to join a clinical trial testing a drug on people at risk for developing them. To participate, volunteers couldn’t have cognitive impairment. But they needed to test positive for a biomarker that put them at higher risk for mental decline ― deposits of a sticky toxic protein in the brain called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The EPA's new lead rule: How one expert crunched the numbers

WSS

Thermo Fisher plant for manufacturing gene therapies to expand

Biotech lab space demand falls sharply

Why are Kaiser Permanente staff considering a strike?

As biotech industry slumps, bioscience job market is upside down

ReNAgade cuts staff seven months after raising $300 million

Pediatric cancer treatments threatened by a new FDA policy

leisure time

knowledge

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

ChatGPT in medicine: STAT answers readers' burning questions

Medical student insurance fails on mental health care coverage

Trump demands the U.S. pay no more for drugs than other countries … again

Drug for rare kidney disease narrowly misses mark in clinical trial

Medical leaders decry Supreme Court decision on affirmative action

CDC's new outbreak response network to include Northeastern

Tori Bowie and the unacceptable rates of Black maternal death

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

knowledge

Diagnostic tests are hitting their mathematical limits

Experts study whether long Covid risk adds up with each reinfection

How AI helped researchers track recovery from depression

Drug for rare kidney disease narrowly misses mark in clinical trial

FDA panel to weigh approval of NurOwn, controversial ALS drug

Despite FDA concern, risk that CAR

hotspot

focus

knowledge

focus